Cetuximab
- Generic Name
- Cetuximab
- Brand Names
- Erbitux
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 205923-56-4
- Unique Ingredient Identifier
- PQX0D8J21J
- Background
Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelia...
- Indication
Cetuximab indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. It is indicated for treating a recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. It is indicated for r...
- Associated Conditions
- Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Metastatic Colorectal Cancer (CRC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Regionally Advanced Squamous Cell Carcinoma of the Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Associated Therapies
- -
Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)
- Conditions
- Interventions
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2016-12-09
- Lead Sponsor
- US Oncology Research
- Target Recruit Count
- 115
- Registration Number
- NCT00661492
- Locations
- 🇺🇸
Paris Regional Cancer Center, Paris, Texas, United States
🇺🇸Melbourne Internal Medicine Associates, Melbourne, Florida, United States
🇺🇸Northern AZ Hematology & Oncology Assoc, Sedona, Arizona, United States
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-04-10
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 344
- Registration Number
- NCT00655876
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸UPMC - Shadyside, Pittsburgh, Pennsylvania, United States
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2016-05-23
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 89
- Registration Number
- NCT00645593
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Stanford University, Stanford, California, United States
Cetuximab as Induction Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)
- Conditions
- Interventions
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 92
- Registration Number
- NCT00623558
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 13
- Registration Number
- NCT00611858
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Vanderbilt Medical Center, Nashville, Tennessee, United States
Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux
- Conditions
- Interventions
- First Posted Date
- 2008-02-07
- Last Posted Date
- 2020-04-15
- Lead Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
- Target Recruit Count
- 406
- Registration Number
- NCT00609284
- Locations
- 🇫🇷
Centre hospitalier Annecy, Annecy, France
🇫🇷Centre hospitalier de Bretagne Sud, Lorient, France
🇫🇷Centre Jean Perrin, Clermont Ferrand, France
Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-targeted Therapy" in Breast Cancer.
- Conditions
- First Posted Date
- 2008-01-24
- Last Posted Date
- 2014-03-20
- Lead Sponsor
- Centre Jean Perrin
- Target Recruit Count
- 35
- Registration Number
- NCT00600249
- Locations
- 🇫🇷
Hôpital Georges Pianta, Thonon les Bains, France
🇫🇷Centre Jean Perrin, Clermont-Ferrand, France
🇫🇷CHU Albert Michallon, Grenoble, France
Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)
- Conditions
- Interventions
- First Posted Date
- 2008-01-23
- Last Posted Date
- 2015-12-03
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT00599131
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)
- Conditions
- Interventions
- First Posted Date
- 2008-01-23
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT00598975
- Locations
- 🇺🇸
Investigator Site - Scottsdale, Scottsdale, Arizona, United States
🇺🇸Investigator Site - Tyler, Tyler, Texas, United States
🇺🇸Investigator Site - Louisville, Louisville, Kentucky, United States
Phase I/II Combination With Irinotecan- Erbitux
- Conditions
- Interventions
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2015-11-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 38
- Registration Number
- NCT00594984
- Locations
- 🇺🇸
Usc/Norris Comprehensive Cancer Center Hospital, Los Angeles, California, United States
🇺🇸Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Washington University, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.